3/5/2021 6:47:57 AM
Lilly Publishes Data From Pirtobrutinib Global Phase 1/2 BRUIN Clinical Trial
3/4/2021 6:58:02 AM
Lilly Announces Results From 40-week SURPASS-2 Clinical Trial Of Tirzepatide
3/3/2021 6:47:12 AM
Lilly : Phase 3 Study On Baricitinib Meets Primary Endpoint Of Hair Regrowth Across Both Dosing Regimens
2/26/2021 7:02:46 AM
Lily: U.S. Government Agrees To Buy Minimum Of 100K Doses Of Bamlanivimab 700 Mg And Etesevimab 1400 Mg Together
2/25/2021 6:46:37 AM
Welldoc, Eli Lilly Announce Collaboration And Licensing Agreement To Integrate Software Into Connected Insulin Solutions
2/18/2021 6:34:55 AM
Lilly, Rigel Announce Global License Agreement To Co-develop Rigel's R552 In All Indications
2/17/2021 6:47:06 AM
Lilly: Tirzepatide Reduced A1C, Body Weight In People With Type 2 Diabetes In Two Phase 3 Trials From SURPASS Program
2/17/2021 6:31:54 AM
Eli Lilly Names Kimberly Johnson As New Board Member
2/9/2021 7:38:17 PM
Lilly's Bamlanivimab Administered With Etesevimab Receives FDA Emergency Use Authorization For COVID-19
2/9/2021 7:01:51 AM
Lilly Appoints Anat Ashkenazi As SVP And CFO